Journal
AIDS
Volume 16, Issue 17, Pages 2344-2347Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/00002030-200211220-00019
Keywords
-
Categories
Ask authors/readers for more resources
A combination of highly active antiretroviral therapy (HAART) and liposomal anthracycline chemotherapy is the standard of care for advanced HIV-associated Kaposi's sarcoma, despite concerns that the chemotherapy may adversely affect lymphocyte subsets and HIV viraemia. We showed in 50 patients that liposomal anthracyclines used with HAART did not lead to a significant loss of CD4 or CD8 cells or an increase in HIV-1 viral load during or up to 12 months after chemotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available